ANNUAL REPORT 2021
LUNDBECK
ANNUAL REPORT 2021
= CONTENTS
27/111
COMMITMENT TO DIVERSITY IN CLINICAL TRIALS
Lundbeck understands that brain diseases wreak havoc
without bias. Whether it be genetics, age, race, sex,
ethnicity, socioeconomics or access to healthcare,
understanding and fully evaluating the multitude of factors
that influence a person's health are key to both the
development of good medicine and equitable advances in
brain health. As part of our ongoing commitment to sustain a
diverse clinical trial infrastructure, the Lundbeck Diversity
Steering Team established the below Clinical Trial Diversity
Principles and committed to tracking and monitoring
progress against them.
Develop & Execute a Clear Strategy to Achieve Diversity
in Our Trials Globally
We aim for each trial to be designed with intention to ensure
participants mirror the full diversity of the patient population
in the country or region AND the disease we are studying.
This will require a concentrated effort to involve
underrepresented populations in our marketed regions
through focused patient-inclusion criteria; attention to the
diversity of clinical trial sites and investigators; removal of
barriers that could impede the participation of certain groups
in clinical trials; and use of real-world data to inform
development efforts and improve understanding of diseases
and products.
Collaborate with Patient Advocacy Groups Choosing to
Make Diversity a Priority
Lundbeck has a longstanding focus on community outreach,
and we are committed to expanding partnerships with
organizations that possess a like-minded focus on diversity.
In collaboration with external partners, we strive to establish
trust with diverse patient and caregiver populations, gain
deeper insight into unmet patient needs and build
awareness about open clinical trials to further enhance the
diversity of our clinical trials.
Implement Integrated Oversight Approach to Inform,
Analyze and Act
We aim to continuously inform and reform our internal
thinking and processes by actively monitoring clinical trial
diversity targets and utilizing real-world data to ensure we
are driving inclusion of underrepresented populations in our
clinical trials.View entire presentation